Ken Galbraith
Amministratore Delegato presso ZYMEWORKS INC.
Patrimonio netto: 192 710 $ in data 30/04/2024
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Neil Klompas | M | 52 |
Zymeworks BC, Inc.
 Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 17 anni |
| Pierre Laurin | M | 63 |
Liminal BioSciences Ltd.
 Liminal BioSciences Ltd. BiotechnologyHealth Technology Part of Liminal R & D BioSciences, Inc., Liminal BioSciences Ltd. is a British biopharmaceutical company founded in 2015. The company is based in Comberton, UK. The company is focused on the discovery and development of novel, small molecule drug candidates. | 30 anni |
| Damian Lamb | M | 52 |
Genesys Capital Partners, Inc.
 Genesys Capital Partners, Inc. Investment ManagersFinance Genesys Capital Partners Inc (Genesys Capital) is an independent venture capital firm founded in 2000 by Damian Lamb, Plumley and Kelly Holman. The firm is headquartered in Toronto. | 24 anni |
| Michael McElhaugh | M | 50 | 10 anni | |
| Hollings Renton | M | 77 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 7 anni |
| Troy Cox | M | 60 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 5 anni |
| Susan Mahony | M | 59 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 5 anni |
| Kelvin Neu | M | 50 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 4 anni |
| Christopher Astle | M | 45 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 3 anni |
| Kenneth Hillan | M | 63 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 7 anni |
| Gary Bridger | M | 61 |
Five Corners Capital, Inc.
 Five Corners Capital, Inc. Investment ManagersFinance Five Corners Capital Inc (Five Corners Capital) is a venture capital firm founded in 2013 by Kenneth Galbraith and Gary Bridger. The firm is headquartered in British Columbia, Canada. | 11 anni |
| Daniel Dex | M | - |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 7 anni |
| Martin Murphy | M | 55 |
Syncona Partners LLP
 Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | 12 anni |
| Murielle Lortie | F | 54 | 6 anni | |
| Jennifer Kaufman-Shaw | M | 74 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.
QLT, Inc.
 QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | 21 anni |
| David Jeans | M | 74 |
Liminal BioSciences Ltd.
Liminal BioSciences Ltd. BiotechnologyHealth Technology Part of Liminal R & D BioSciences, Inc., Liminal BioSciences Ltd. is a British biopharmaceutical company founded in 2015. The company is based in Comberton, UK. The company is focused on the discovery and development of novel, small molecule drug candidates. | 8 anni |
| John Edward Moran | M | 79 |
Liminal BioSciences Ltd.
Liminal BioSciences Ltd. BiotechnologyHealth Technology Part of Liminal R & D BioSciences, Inc., Liminal BioSciences Ltd. is a British biopharmaceutical company founded in 2015. The company is based in Comberton, UK. The company is focused on the discovery and development of novel, small molecule drug candidates. | 12 anni |
| Carlos Campoy | M | 60 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 1 anni |
| Bruce Wendel | M | 70 |
Liminal BioSciences Ltd.
Liminal BioSciences Ltd. BiotechnologyHealth Technology Part of Liminal R & D BioSciences, Inc., Liminal BioSciences Ltd. is a British biopharmaceutical company founded in 2015. The company is based in Comberton, UK. The company is focused on the discovery and development of novel, small molecule drug candidates. | 16 anni |
| Kelly Holman | M | - |
Genesys Capital Partners, Inc.
Genesys Capital Partners, Inc. Investment ManagersFinance Genesys Capital Partners Inc (Genesys Capital) is an independent venture capital firm founded in 2000 by Damian Lamb, Plumley and Kelly Holman. The firm is headquartered in Toronto. | 24 anni |
| Kurt Stefan Victor Clulow | M | 53 |
Liminal BioSciences Ltd.
Liminal BioSciences Ltd. BiotechnologyHealth Technology Part of Liminal R & D BioSciences, Inc., Liminal BioSciences Ltd. is a British biopharmaceutical company founded in 2015. The company is based in Comberton, UK. The company is focused on the discovery and development of novel, small molecule drug candidates. | 10 anni |
| Timothy Steven Wach | M | 63 | 5 anni | |
| Jack Spinks | M | - |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 1 anni |
| Marie Iskra | F | 48 | 5 anni | |
| Lisa Bright | F | 56 |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | - |
| Tom Collings | M | - |
Kalium Health Ltd.
 Kalium Health Ltd. Medical SpecialtiesHealth Technology Kalium Health Ltd. engages in the provision of clinical, technological, and healthcare services. It provides personalized electrolyte monitoring. The company was founded by Fiona Karet and Tom Collings and is headquartered in Cambridge, the United Kingdom. | - |
| Kaycia Wilde | M | - |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 3 anni |
| Diana Papove | F | - |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 4 anni |
| Fiona Karet | F | - |
Kalium Health Ltd.
Kalium Health Ltd. Medical SpecialtiesHealth Technology Kalium Health Ltd. engages in the provision of clinical, technological, and healthcare services. It provides personalized electrolyte monitoring. The company was founded by Fiona Karet and Tom Collings and is headquartered in Cambridge, the United Kingdom. | - |
| Jay Siegel | M | 71 | 7 anni | |
| Jennifer Williams | F | - |
Genesys Capital Partners, Inc.
Genesys Capital Partners, Inc. Investment ManagersFinance Genesys Capital Partners Inc (Genesys Capital) is an independent venture capital firm founded in 2000 by Damian Lamb, Plumley and Kelly Holman. The firm is headquartered in Toronto. | 22 anni |
| Jeffrey Peters | M | 53 | 9 anni | |
| Andrew Cossar | M | - |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | 7 anni |
| Derek Miller | M | 54 | 1 anni | |
| Kris Shah | M | 63 | 2 anni | |
| Brian Robert Ellacott | M | 67 | 6 anni | |
| Mark Fowlie | M | - |
AudienceView Ticketing Corp.
 AudienceView Ticketing Corp. Packaged SoftwareTechnology Services AudienceView Ticketing Corp. engages in the provision and development of software and media solutions for ticket sales. It offers services through its platform, which under the brands of OvationTix, Vendini, TheaterMania, WhatsOnStage, LaughStub, ElectroStub, and TuneStub. The company was founded by Kevin Kimsa and Paul J. Atkinson in 2002 and is headquartered in Toronto, Canada. | 12 anni |
| David Stump | M | 74 | 11 anni | |
| Arthur Rosenthal | M | 77 | 6 anni | |
| Kevin Kimsa | M | - |
AudienceView Ticketing Corp.
AudienceView Ticketing Corp. Packaged SoftwareTechnology Services AudienceView Ticketing Corp. engages in the provision and development of software and media solutions for ticket sales. It offers services through its platform, which under the brands of OvationTix, Vendini, TheaterMania, WhatsOnStage, LaughStub, ElectroStub, and TuneStub. The company was founded by Kevin Kimsa and Paul J. Atkinson in 2002 and is headquartered in Toronto, Canada. | 22 anni |
| Federica O’Brien | F | 66 | 3 anni | |
| Alek Krstajic | M | 60 | 4 anni | |
| Mark Hollywood | M | 55 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 5 anni |
| Chris Hollowood | M | 50 |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | 12 anni |
| Eric Risser | M | 51 | 15 anni | |
| Paul Moore | M | 58 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 2 anni |
| Karen Ferrante | M | 66 | 7 anni | |
| Scott Jackson | M | 59 | 7 anni | |
| Derek Miller | M | - |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | - |
| Alasdair Moodle | M | - |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | - |
| Lucas Donigian | M | - | 4 anni | |
| Markus John | M | - |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | - |
| William Dutson | M | - |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | - |
| Catherine Graham | F | - | 6 anni | |
| Alice Renard | M | - |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | 7 anni |
| Michael Hayden | M | 72 |
University of British Columbia
| 41 anni |
| Sarah Farr | F | - |
Genesys Capital Partners, Inc.
Genesys Capital Partners, Inc. Investment ManagersFinance Genesys Capital Partners Inc (Genesys Capital) is an independent venture capital firm founded in 2000 by Damian Lamb, Plumley and Kelly Holman. The firm is headquartered in Toronto. | 4 anni |
| Gonzalo Garcia | M | - |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | 4 anni |
| Andy S. Gesell | M | 56 |
AudienceView Ticketing Corp.
AudienceView Ticketing Corp. Packaged SoftwareTechnology Services AudienceView Ticketing Corp. engages in the provision and development of software and media solutions for ticket sales. It offers services through its platform, which under the brands of OvationTix, Vendini, TheaterMania, WhatsOnStage, LaughStub, ElectroStub, and TuneStub. The company was founded by Kevin Kimsa and Paul J. Atkinson in 2002 and is headquartered in Toronto, Canada. | - |
| Rolf Soderstrom | M | 58 |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | - |
| Gwenaelle Pemberton | F | - |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | 2 anni |
| Roel Bulthuis | M | - |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | 1 anni |
| Stephen Eck | M | 69 | 4 anni | |
| Laura O’Connor | F | - | 4 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Ali Tehrani | M | 52 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 19 anni |
| Steven Plymale | M | - | - | |
| Lota Zoth | F | 64 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 7 anni |
| Bill Adams | M | 62 |
AnorMED, Inc.
 AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases.
University of British Columbia
| 14 anni |
| Paulo Costa | M | 73 | 13 anni | |
| Stanford J. Stewart | M | 71 | 8 anni | |
| Natalie Sacks | M | 59 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 6 anni |
| Jim J. Miller | M | 64 |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | 10 anni |
| Michael Jeffrey Abrams | M | 68 |
AnorMED, Inc.
AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | 10 anni |
| Nick Bedford | M | 64 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | 16 anni |
| Anthony G. Phillips | M | - |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | 10 anni |
| Christopher S. James | M | - | 1 anni | |
| Terry Hamilton | M | 61 |
University of British Columbia
| 5 anni |
| Peeyush Varshney | M | 57 |
University of British Columbia
| 8 anni |
| Martin MacLachlan | M | - |
University of British Columbia
| 5 anni |
| Mary Garden | F | 65 |
University of British Columbia
| 6 anni |
| Chris McLeod | M | 63 |
University of British Columbia
| 6 anni |
| Eran Nadav | M | 55 | - | |
| Chun Ning Shih | M | 60 |
University of British Columbia
| 6 anni |
| Wajida Leclerc | F | 64 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | 10 anni |
| David Matousek | M | - |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | - |
| Malcolm J. P. Finlayson | M | - |
University of British Columbia
| 7 anni |
| Samira Sakhia | F | 55 | 2 anni | |
| Kenneth R. Burgess | M | - |
University of British Columbia
| 5 anni |
| Richard George Whatley | M | - |
University of British Columbia
| 9 anni |
| Suzanne Wood | F | 67 |
University of British Columbia
| 6 anni |
| Robert Obst | M | - | - | |
| Brian Leeners | M | 58 |
University of British Columbia
| 7 anni |
| Paul Bowes | M | - |
University of British Columbia
| 4 anni |
| George Gorzynski | M | - |
University of British Columbia
| 4 anni |
| Darrin Erickson | M | - |
University of British Columbia
| 5 anni |
| Arnold Lewis Oronsky | M | 83 | 14 anni | |
| Gregg Saretsky | M | 64 |
University of British Columbia
| 6 anni |
| Donald Lee Drakeman | M | 70 |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | - |
| Michael Steinmetz | M | 75 | 13 anni | |
| Ryan Dercho | M | - |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | - |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Canada | 66 | 66.00% |
| Stati Uniti | 37 | 37.00% |
| Regno Unito | 19 | 19.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Ken Galbraith
- Contatti personali
